RACIAL DISPARITIES IN UTILIZATION OF ASTHMA CONTROLLER MEDICATIONS

Vidyas 1, Huftadera MA, Ganguli A 1
1University of Tennessee, Memphis, TN, USA; 2University of Tennessee Health Science Center, Memphis, TN, USA

OBJECTIVES: Despite the recommendations from national guidelines, under-use of controller drugs (corticosteroids and anti-inflammatory drugs) still persists among asthma patients. This study examined whether demographic disparities exist in utilizing controller drugs. METHODS: The data came from four states (California, Illinois, Texas, and Alabama) sample of 2004 National Asthma Survey. Study population included asthma patients that reported occurrence of at least one asthma attack in a 12 months period and were able to produce their drugs at the time of interview. Multiple logistic regression was used to determine the relationship between predictor variables and odds of using controller drugs. RESULTS: A total of 1824 asthma patients that reported at least one asthma attack in a 12 months period had their drugs available at the time of interview. African Americans (OR = 0.829, 95% CI: 0.820, 0.838), Hispanics (OR = 0.826, 95% CI: 0.817, 0.834) and Children (age 0–17) (OR = 0.575; 95% CI: 0.570, 0.580), were less likely to utilize asthma controller drugs. When interaction effects between age and race were introduced, African American children had significantly less likelihood (OR = 0.499, 95% CI: 0.489, 0.508) of using controller drug. On the other hand, even though the Hispanic population was less likely to utilize controller drugs, Hispanic children were slightly more likely to utilize them. (OR = 1.078; 95% CI: 1.061, 1.096). CONCLUSIONS: Although the underuse of controller drugs persists among overall asthma population, demographic disparities exist. Our results support attempts to increase access to controller drugs among African Americans, Children and Hispanic asthma population.

QUALITY OF LIFE EVALUATION OF PATIENTS WITH NON-TRANSMISSIBLE CHRONIC DISEASES ENROLLED IN A PHARMACY BENEFIT MANAGEMENT

Reit Nino 1, Tower C

 OBJECTIVES: Evaluation of the quality of life of patients with non-transmissible chronic diseases (NTCD) enrolled in a pharmacy benefit management (PBM) program. METHODS: An adapted version of the 12-item Health Survey (SF-12) questionnaire was performed on 9753 beneficiaries of a PBM program for patients with NTCD, among them 42.5% (n = 4149) answered the questionnaire. The results were analyzed considering diseases characteristics and a health service utilization and medical expenses. Variables were expressed in averages, standard deviation (SD) and confidence interval (CI) of 95%. RESULTS: The mean age was 62.9 years old. The female sex represented 52% of the total. Among the beneficiaries who filled the questionnaire, 56.3% referred one NTCD, 30.7% referred two diseases and 13.0% mentioned three or more morbid conditions. High blood pressure was the most prevalent disease (86.5%), followed by diabetes (24.1%), coronary heart disease (23.1%), Chronic obstructive pulmonary disease (7.6%), congestive heart failure (CHF;7.4%), and cerebrovascular disease (CVD;6.2%). Physical functioning (41.6%) and vitality (45.5%) represented the SF-12 dimensions with the lowest scores. The highest scores were observed for social functioning (65.3%) and pain (65.2%). The mean values for the SF-12 physical component summary (PCS-12) was 39.9 (CI 39.6;40.2) and the mental component summary (MCS-12) was 49.1 (CI 44.7;45.4). Age (r = 0.99 PCS / t = 0.71 MCS), number of morbidities (r = 0.99 PCS / t = 0.96 MCS), per capita annual expenses (r = 0.99 PCS / t = 0.93 MCS) and type of disease were the variables with the highest correlations with SF-12 summary scores. CONCLUSIONS: Best results for quality of life were observed among the younger people and individuals with less number of chronic diseases. The CVD and CHF had the worst averages for PCS-12 and MCS-12 summary scores. The same was observed for individuals with multiple morbidities, higher health service utilization and medical expenses.

SMOKING-ATTRIBUTABLE BURDEN OF FOUR TOBACCO-RELATED DISEASES IN COLOMBIA IN 2007

Narváez J, Añas N, de la Haci F, Orozco J, Porras A

 Universidad Nacional de Colombia, Bogotá D.C., Colombia; Universidad de Cartagena, Cartagena, Colombia; AFGES Consultoría S.A., Cartagena, Colombia

OBJECTIVES: Estimating disease burden for lung cancer, chronic obstructive pulmonary disease (COPD), coronary heart disease (CHD) and stroke in the adult Colombian population during 2007, and the smoking-attributable fraction of such burden. METHODS: A systematic review was done to identify the incidence, prevalence and mortality of the studied diseases in Colombia. This was complemented with other sources of information, such as the Colombian statistical administrative department (DIAN) and International Agency for Research on Cancer (IARC) databases. DSMOD II software was used to verify and integrate the obtained estimators. These estimators were used to calculate the number of years of life lost (YLL). Similar review procedures were used to estimate smoking prevalence by gender and age group. A set of relative risks for the four diseases according to smoking status and age group was used to estimate the smoking-attributable burden. Relative risks were taken from the BENESCO (Benefits of Smoking Cessation on Outcomes) model. RESULTS: Total burden for lung cancer in 2007 was estimated in 34,593 YLL, 127,992 YLL for COPD, 399,260 YLL for CHD and 161,715 YLL for stroke. The four diseases cause 714,550 YLL each year, taking the smoker and non-smoker populations as a whole. Considering that about 20% of the adult Colombians smoke, after 20 years this group would have accumulated 661,825 YLL directly attributable to smoking; these YLL could have been avoided in a hypothetical situation in which smoking habit is completely eliminated. CONCLUSIONS: The smoking-attributable burden represents only a fraction of the total burden for these diseases; nevertheless, such percentage is important because it is at least partially preventable. With just 25% of smokers making an attempt to quit using the best available therapy the Colombia (varenicline efficacy after one year: 22.4%), then more than 4,600 deaths and 27,000 YLLs could be avoided by the end of the 20 years horizon.